CD30 monoclonal antibodies 

Monoclonal antibodies used in immunotherapy are produced artificially from a cell clone therefore consist of a single type of immunoglobulin. They are targeted towards specific antigens and bind to the antigens to form a complex. The complex can be recognized and destroyed by phagocytes or used for other diagnostic purposes. CD30 has been identified as a marker on Reed–Sternberg cells in Hodgkin lymphoma and cells in other specific types of lymphoma. CD30 monoclonal antibodies may be used to treat Hodgkin’s lymphoma or anaplastic large cell lymphoma.

An anti-CD3 monoclonal antibody is one that binds to CD3 on the surface of T cells. They are immunosuppresive drugs. The first to be approved was muromonab-CD3 in 1986, to treat transplant rejection. Newer monoclonal antibodies with the same mechanism of action include otelixizumab, teplizumab and visilizumab.

CD30 is a surface marker for neoplastic cells of Hodgkin’s lymphoma and shows sequence homology to members of the tumor necrosis factor (TNF) receptor superfamily.